6,019 Shares in Gilead Sciences, Inc. (GILD) Purchased by Roosevelt Investment Group Inc.

Roosevelt Investment Group Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,019 shares of the biopharmaceutical company’s stock, valued at approximately $376,000.

Several other large investors also recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC lifted its stake in Gilead Sciences by 646.6% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 4,069 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 3,524 shares during the last quarter. Addenda Capital Inc. lifted its stake in Gilead Sciences by 2.3% during the fourth quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock valued at $3,735,000 after purchasing an additional 1,362 shares during the last quarter. S&CO Inc. lifted its stake in Gilead Sciences by 5.5% during the fourth quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 330 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in Gilead Sciences by 6.2% during the third quarter. Meeder Asset Management Inc. now owns 100,070 shares of the biopharmaceutical company’s stock valued at $7,726,000 after purchasing an additional 5,841 shares during the last quarter. Finally, IMA Wealth Inc. lifted its stake in Gilead Sciences by 31.6% during the fourth quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock valued at $445,000 after purchasing an additional 1,710 shares during the last quarter. 77.76% of the stock is owned by institutional investors.

Gilead Sciences stock opened at $65.55 on Friday. The company has a market capitalization of $86.65 billion, a price-to-earnings ratio of 10.66, a P/E/G ratio of 4.22 and a beta of 1.19. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $82.71.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.78 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.84%. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio is currently 37.07%.

Several analysts recently commented on GILD shares. Raymond James cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “strong-buy” rating for the company in a research note on Tuesday, February 12th. Piper Jaffray Companies lowered shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and cut their target price for the company from $85.00 to $75.00 in a research note on Friday, October 26th. Morgan Stanley boosted their price target on shares of Gilead Sciences from $85.00 to $86.00 and gave the company an “equal weight” rating in a report on Wednesday, December 19th. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $83.59.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the transaction, the director now owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. 1.16% of the stock is currently owned by corporate insiders.

WARNING: “6,019 Shares in Gilead Sciences, Inc. (GILD) Purchased by Roosevelt Investment Group Inc.” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2019/02/22/6019-shares-in-gilead-sciences-inc-gild-purchased-by-roosevelt-investment-group-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Convertible Shares

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit